Wells Fargo raises Travere Therapeutics target to $65

0 min read Updated on 12 Jun 2026, 07:22 PM

Reviewed by

Radhika SScanX News Team

AI Summary

Wells Fargo analyst Mohit Bansal maintains an Overweight rating on Travere Therapeutics and raises the price target to $65 from $50, indicating a positive outlook.

*this image is generated using AI for illustrative purposes only.

Wells Fargo analyst Mohit Bansal has maintained an Overweight rating on Travere Therapeutics and increased the price target to $65 from $50. The revised target reflects a more optimistic outlook for the company's stock performance.

Rating and Price Action

The brokerage firm continues to endorse the stock with a positive stance, citing the potential for upside. The adjustment in the price target signifies a shift in valuation expectations following recent analysis.

Metric	Previous	New
Rating	Overweight	Overweight
Price Target	$50	$65

What specific factors drove Wells Fargo to increase the price target by 30%?

How might this rating upgrade influence investor sentiment toward Travere Therapeutics in the short term?

What upcoming clinical trial results or regulatory decisions could further impact the stock's performance?

Read Next Article

Travere Therapeutics grants 32,000 RSUs to new employees

1 min read Updated on 12 Jun 2026, 02:38 AM

Reviewed by

Jubin VScanX News Team

Add as a preferred
source on Google

AI Summary

Travere Therapeutics granted 32,000 RSUs to six new employees on June 10, 2026, under Nasdaq Rule 5635(c)(4). The RSUs vest over four years, with 25% vesting annually, subject to continued service.

*this image is generated using AI for illustrative purposes only.

Travere Therapeutics, Inc. granted inducement equity awards covering an aggregate of 32,000 shares of its common stock to six new employees on June 10, 2026. The awards consist of inducement restricted stock units (RSUs), which were approved by the Compensation Committee of the Board of Directors. These grants were issued as material inducements for the individuals entering into employment with Travere Therapeutics in accordance with Nasdaq Listing Rule 5635(c)(4).

The RSUs are subject to the terms of Travere's 2018 Equity Incentive Plan but were granted outside of the plan. The vesting schedule is structured over four years, with 25% of the shares vesting on each anniversary of the grant date. Vesting is contingent upon the new employee's continued service relationship with Travere Therapeutics through the applicable vesting dates.

Grant Details

Detail	Information
Grant Date	June 10, 2026
Total Shares Granted	32,000
Recipients	6 new employees
Vesting Period	4 years
Vesting Schedule	25% annually

The grants were specifically authorized as an employment inducement under Nasdaq Listing Rule 5635(c)(4). This rule allows companies to issue equity awards to new employees as a material inducement to enter into employment, provided the awards are not granted under an existing equity plan unless specifically approved for such purposes.

What specific roles or expertise do these six new hires bring to Travere Therapeutics?

Will Travere Therapeutics continue to utilize inducement awards outside the 2018 Equity Incentive Plan for future hiring?

How might these grants impact the company's share dilution and overall compensation expenses over the next four years?